Clinical Trials Logo

Signs and Symptoms, Respiratory clinical trials

View clinical trials related to Signs and Symptoms, Respiratory.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06156449 Recruiting - Patient Engagement Clinical Trials

Effect of Thyme Oil on Respiratory Symptoms and Hemodynamic Parameters in COPD Patients

Start date: November 15, 2023
Phase: N/A
Study type: Interventional

Chronic Obstructive Pulmonary Disease (COPD) is a high-prevalence, preventable and treatable disease characterized by abnormal respiratory symptoms and airway obstruction, often resulting from exposure to hazardous substances due to airway and/or alveolar abnormalities. The disease is an important problem with high morbidity and mortality rates all over the world and in our country. COPD is known as the third disease with a high mortality rate and the sixth disabling disease worldwide. The Global Burden of Disease Study reports 251 million cases of COPD worldwide in 2016. According to World Health Organization (WHO) data, it is estimated that 3.17 million deaths were caused by COPD in 2015. This number constitutes 5% of all deaths. More than 90% of these deaths occur in low- and middle-income countries.It has become common to use medicinal plants together with medical antiviral treatments to reduce the negative effects of COPD. Pulmonary elimination of thymol has been reported to have beneficial effects on respiratory diseases. Our research is the first to investigate in detail the effects of thyme oil on the symptoms and hemodynamic parameters of COPD. The widespread use of the thyme plant among patients shows that the research is important because it is an easily accessible, cheap and reliable essential oil.

NCT ID: NCT06006325 Recruiting - Sepsis Clinical Trials

Electroacupuncture Modulates SPMs Metabolism and Respiratory Symptoms in Patients With Sepsis Complicating ARDS

Start date: August 20, 2023
Phase: N/A
Study type: Interventional

In this interventional clinical trial, researchers will administer electroacupuncture versus sham electroacupuncture to sepsis patients with ARDS and collect objective outcome measures. The study will be divided into 2 groups. The EA group will receive electroacupuncture and the SHAM-EA group will receive sham electroacupuncture. The purpose of this study is to investigate the effect of electroacupuncture on the synthesis of SPMs in sepsis patients with ARDS.

NCT ID: NCT05837585 Recruiting - Technology Clinical Trials

The Effectiveness of Air Quality Sensor in Elderly Residential Setting

Start date: June 6, 2023
Phase: N/A
Study type: Interventional

The study has 7 research questions regarding the use of the air quality sensor in residential care home for the elderly: Primary study questions: 1. Can the real-time monitoring of air quality and the subsequent activities to improve air quality and long-term measures reduce respiratory symptoms? Secondary study questions: 2. Can the real-time monitoring of air quality and the subsequent activities to improve air quality and long-term measures reduce pulse rate, systolic blood pressure and diastolic blood pressure? 3. What are the activities to improve air quality and long-term measures that aim to improve air quality, including the rationales for change and non-change of the measures? 4. What are the changes in air quality indexes recorded by the air quality sensor? Auxiliary study questions: 5. How many days do the residents feel sick and stay in hospitals? 6. What are the perceived benefits and feasibility of the air quality sensor?

NCT ID: NCT05794815 Recruiting - Clinical trials for Respiratory Infection (for Example, Pneumonia, Bronchitis)

Modulation of Gut Microbiota by Probiotic in Children With Respiratory Symptoms

Start date: May 1, 2023
Phase: N/A
Study type: Interventional

This project aims to study the benefits of probiotics namely Bifidobacterium infantis YLGB-1496 in modulating gut microbiota of children with respiratory symptoms, among pre-school children in Malaysia aged >12 months old, <7 years old.

NCT ID: NCT05656482 Recruiting - Rhinitis, Allergic Clinical Trials

Ability of a Cat Food to Reduce Respiratory Symptoms in Cat Allergic Patients

CATS
Start date: May 6, 2022
Phase:
Study type: Observational

Cat allergy is the most common animal allergy, affecting approximately 1 in 5 adults worldwide. The prevalence of allergy to furry animals is increasing, and cat allergy is a major risk factor for the development of asthma and rhinitis. Fel-d1 is the major feline allergen, to which 95% of cat allergic people react. All cats produce Fel-d1 regardless of breed, age, coat type, sex or weight. Fel-d1 is contained primarily in the saliva and sebum of cats. This allergy manifests itself as allergic rhinitis (AR) (sneezing, cold, coughing, conjunctivitis with watering and itching), severe asthma, and irritation and swelling of the skin when scratched. A new approach to managing cat allergies is to neutralize the allergens at the source by feeding domestic cats a diet containing anti-Fel-d1 IgY antibodies. The purpose of this pilot study is to determine whether feeding domestic cats a food containing an egg product with anti-Fel d1 IgY (PRO PLAN® LIVECLEAT®) induces a reduction of allergic symptoms in their owners.

NCT ID: NCT05544942 Recruiting - Clinical trials for Respiratory Symptoms

GCWB1001 Evaluates the Effectiveness and Safety of Respiratory Health

Start date: August 23, 2022
Phase: N/A
Study type: Interventional

This human application test was designed to evaluate the effectiveness and safety of the losing suction tendon, compared to the control food when the GCWB1001 was consistent with the symptoms of the respiratory symptoms of mildness.

NCT ID: NCT04695704 Recruiting - Covid19 Clinical Trials

Efficacy of Montelukast in Mild-moderate Respiratory Symptoms in Patients With Long-COVID-19:

E-SPERANZA
Start date: August 1, 2021
Phase: Phase 3
Study type: Interventional

Recently, a new clinical presentation called "long covid" has been reported, for patients with symptoms lasting for more than 4 weeks from the onset of the disease. Typically, the symptoms comprise dyspnea, cough, headache, arthralgia, fever, abdominal pain, asthenia and skin manifestations This project aims to evaluate the efficacy of Montelukast in improving the quality of life associated with respiratory symptoms in patients with persistent COVID-19 symptoms. The main objective is to compare the efficacy of low-dose Montelukast versus placebo to improve respiratory symptoms in patients with persistent COVID-19 symptoms.

NCT ID: NCT02913365 Recruiting - Lung Cancer Clinical Trials

Etiologies, Investigations and Outcomes of Patients Presenting With Hemoptysis

Start date: October 2012
Phase: N/A
Study type: Observational

The study consist of a retrospective analysis of the etiologies, investigations and outcomes of patients presenting between 2005 to 2010 with hemoptysis in a North-American Tertiary center.

NCT ID: NCT00328029 Recruiting - Clinical trials for Signs and Symptoms, Respiratory

Respiratory Side Effects of Busulfan High Dose Chemotherapy in a Pediatric Population

Start date: July 2006
Phase: Phase 2
Study type: Interventional

Recently, several conditioning regimens did not include total body irradiation (TBI) anymore, especially in the case of young children due to cognitive sequelae and late effects on growth and height. Thus, such effective chemotherapy conditioning regimens were developed to avoid these complications. Busulfan is one of the major drugs used in these treatments, but, is also administered in high dose chemotherapy followed by autograft. In both situations, long term pulmonary side effects were diagnosed in a few cases. Even if the occurrence is not very frequent, the clinical management is a real challenge regarding the reduced quality of life and life expectancy of these patients. Up to now, no correlation was done between respiratory sequelae and busulfan pharmacokinetics. Hence, in the investigators' pediatric onco-hematological unit, a prospective study will begin and last three years to assess the respiratory side effects due to busulfan and their potential links with individual drug pharmacokinetic measures. These results will be compared to patients treated with TBI during the same period of time.